Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 1995, for OXIS International, Inc. (Note: The input metadata referenced "GT Biopharma," but the filing text explicitly identifies the registrant as OXIS International, Inc.). The company operates in the biotechnology sector, focusing on bovine superoxide dismutase (bSOD) and diagnostic assays. In September 1994, the company significantly expanded its operations through the acquisition of Bioxytech S.A. and International BioClinical, Inc. (IBC), which are now included in the consolidated results for the first quarter of 1995 but were not present in the comparable 1994 period.
Key Financial Metrics
| Metric | Q1 1995 | Q1 1994 |
|---|---|---|
| Total Revenues | $2,126,000 | $984,000 |
| Net Loss | $(757,000) | $(187,000) |
| Net Loss Per Share | $(0.08) | $(0.04) |
| Operating Cash Flow | $(899,000) | $492,000 |
| Cash and Equivalents (End of Period) | $724,000 | $1,243,000 |
| Working Capital Deficit | $(1,482,000) | Not Reported |
| Current Liabilities | $4,372,000 | N/A |
| Current Assets | $2,890,000 | N/A |
Margins: Cost of sales as a percentage of product sales decreased from 67% in Q1 1994 to 57% in Q1 1995. However, the company reported an operating loss of $725,000 for the quarter.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased by 116% to $2.126 million, driven primarily by a $948,000 sale of bulk bSOD to Sanofi Winthrop Inc. and the inclusion of acquired companies (Bioxytech and IBC) in the 1995 results.
- Expense Surge: Research and development (R&D) expenses jumped from $216,000 to $1,029,000, largely due to the integration of acquired R&D programs. Selling, general, and administrative (SG&A) expenses nearly doubled to $645,000 due to the acquisitions.
- Liquidity Deterioration: Cash and certificates of deposit declined from $1.432 million at year-end 1994 to $922,000 at March 31, 1995. The company moved from a positive operating cash flow in Q1 1994 to a significant burn of $899,000 in Q1 1995.
- Debt Structure: The company incurred $766,000 in new secured promissory notes from former Bioxytech shareholders in February 1995. Customer deposits decreased significantly by $866,000.
Outlook, Risks, and Management Commentary
Going Concern Warning: Management explicitly states that the company's continuation as a going concern is contingent upon obtaining additional financing. Current liabilities exceed current assets by $1.482 million. If the company fails to raise capital by the end of June 1995, it may be forced to seek bankruptcy protection or reorganization.
Financing Needs: The company is pursuing a private placement of equity securities to raise between $4.5 million and $9.0 million. Pending this, it is attempting to raise an interim $1 million to $2 million. If only the interim amount is raised, the company plans to curtail operations, reduce personnel, and slow R&D.
Key Risks:
- Customer Concentration: Sanofi Winthrop accounted for 35% of 1994 revenues. Future sales depend on the success of Sanofi's Phase III clinical trials for DISMUTEC.
- Regulatory Issues: European sales are declining due to product withdrawals in four countries. Potential withdrawal in Spain could further reduce revenues.
- Capital Availability: There is no assurance that the private placement will be successful or that additional capital will be available to fund operations beyond the second quarter of 1995.
Investor Verification Checklist
- Verify the status and probability of the $4.5M–$9.0M private equity placement.
- Confirm the timeline and results of Sanofi Winthrop's Phase III clinical trials for DISMUTEC.
- Monitor regulatory developments regarding bSOD product withdrawals in Spain and other European markets.
- Assess the company's ability to meet debt obligations, specifically the $766,000 in notes due February 1996 and the $600,000 customer advance due May 1996.
- Review the company's cash burn rate against its current cash balance of $724,000 to determine runway without new financing.